In AML, distinct MDSC subsets have been characterized and specifically the circulating M-MDSC subset (defined as CD14+HLA-DRlow) appeared to be elevated and correlated with a poor prognosis in AML patients (21, 22). This evidence concerns the gene CD14 and acute myeloid leukemia.